• Abbott presented Beta-CORRECT results at ESMO 2026 showing its whole-genome Oncodetect test improved detection of colorectal cancer recurrence versus its whole-exome version.
• The test identified additional patients with residual cancer DNA following surgery, helping assess recurrence risk.
• Detectable cancer DNA was the strongest predictor of recurrence among factors studied; further research will assess implications for patient management.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Abbott Laboratories published the original content used to generate this news brief via PR Newswire (Ref. ID: 202610230915PR_NEWS_USPR_____CG79251) on October 23, 2026, and is solely responsible for the information contained therein.